GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts

Shares of GeoVax Labs, Inc. (NASDAQ:GOVXGet Free Report) have received an average recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Thursday, February 27th.

Get Our Latest Stock Analysis on GeoVax Labs

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at $97,000. Geode Capital Management LLC grew its holdings in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $29,000. Finally, Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $1.54 on Friday. The business’s 50 day simple moving average is $1.85 and its 200 day simple moving average is $2.33. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs Company Profile

(Get Free Report

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

See Also

Analyst Recommendations for GeoVax Labs (NASDAQ:GOVX)

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.